BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zając M, Muszalska I, Sobczak A, Dadej A, Tomczak S, Jelińska A. Hepatitis C - New drugs and treatment prospects. Eur J Med Chem 2019;165:225-49. [PMID: 30685524 DOI: 10.1016/j.ejmech.2019.01.025] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 10.0] [Reference Citation Analysis]
Number Citing Articles
1 LeBlanc EV, Kim Y, Capicciotti CJ, Colpitts CC. Hepatitis C Virus Glycan-Dependent Interactions and the Potential for Novel Preventative Strategies. Pathogens 2021;10:685. [PMID: 34205894 DOI: 10.3390/pathogens10060685] [Reference Citation Analysis]
2 Ejeh S, Uzairu A, Shallangwa GA, Abechi SE, Ibrahim MT. In silico design and pharmacokinetics investigation of some novel hepatitis C virus NS5B inhibitors: pharmacoinformatics approach. Bull Natl Res Cent 2022;46. [DOI: 10.1186/s42269-022-00796-y] [Reference Citation Analysis]
3 Borgia M, Dal Bo M, Toffoli G. Role of Virus-Related Chronic Inflammation and Mechanisms of Cancer Immune-Suppression in Pathogenesis and Progression of Hepatocellular Carcinoma. Cancers (Basel) 2021;13:4387. [PMID: 34503196 DOI: 10.3390/cancers13174387] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
4 Hdoufane I, Bjij I, Oubahmane M, Soliman MES, Villemin D, Cherqaoui D. In silico design and analysis of NS4B inhibitors against hepatitis C virus. J Biomol Struct Dyn 2020;:1-15. [PMID: 33118481 DOI: 10.1080/07391102.2020.1839561] [Reference Citation Analysis]
5 Ryu HC, Windisch M, Lim JW, Choi I, Lee EK, Yoo HH, Kim TK. Thiophen urea derivatives as a new class of hepatitis C virus entry inhibitors. J Enzyme Inhib Med Chem 2021;36:462-8. [PMID: 33455472 DOI: 10.1080/14756366.2020.1870456] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Ejeh S, Uzairu A, Shallangwa GA, Abechi SE. Computational insight to design new potential hepatitis C virus NS5B polymerase inhibitors with drug-likeness and pharmacokinetic ADMET parameters predictions. Futur J Pharm Sci 2021;7. [DOI: 10.1186/s43094-021-00373-6] [Reference Citation Analysis]
7 Onorato L, Pisaturo M, Starace M, Minichini C, Di Fraia A, Astorri R, Coppola N. Virological Factors Associated with Failure to the Latest Generation of Direct Acting Agents (DAA) and Re-Treatment Strategy: A Narrative Review. Viruses 2021;13:432. [PMID: 33800289 DOI: 10.3390/v13030432] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Boonma T, Nutho B, Darai N, Rungrotmongkol T, Nunthaboot N. Exploring of paritaprevir and glecaprevir resistance due to A156T mutation of HCV NS3/4A protease: molecular dynamics simulation study. J Biomol Struct Dyn 2021;:1-12. [PMID: 33430709 DOI: 10.1080/07391102.2020.1869587] [Reference Citation Analysis]
9 Fernandez-Fernandez B, D'Marco L, Górriz JL, Jacobs-Cachá C, Kanbay M, Luis-Lima S, Porrini E, Sarafidis P, Soler MJ, Ortiz A. Exploring Sodium Glucose Co-Transporter-2 (SGLT2) Inhibitors for Organ Protection in COVID-19. J Clin Med 2020;9:E2030. [PMID: 32605278 DOI: 10.3390/jcm9072030] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
10 Freriksen JJM, van Seyen M, Judd A, Gibb DM, Collins IJ, Greupink R, Russel FGM, Drenth JPH, Colbers A, Burger DM. Review article: direct-acting antivirals for the treatment of HCV during pregnancy and lactation - implications for maternal dosing, foetal exposure, and safety for mother and child. Aliment Pharmacol Ther. 2019;50:738-750. [PMID: 31448450 DOI: 10.1111/apt.15476] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
11 Li HC, Yang CH, Lo SY. Hepatitis C Viral Replication Complex. Viruses 2021;13:520. [PMID: 33809897 DOI: 10.3390/v13030520] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Zhang Y, Liu X, Lin Y, Lian B, Lan W, Iovanna JL, Liu X, Peng L, Xia Y. Novel triazole nucleoside analogues promote anticancer activity via both apoptosis and autophagy. Chem Commun 2020;56:10014-7. [DOI: 10.1039/d0cc04660d] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
13 Malik AA, Chotpatiwetchkul W, Phanus-Umporn C, Nantasenamat C, Charoenkwan P, Shoombuatong W. StackHCV: a web-based integrative machine-learning framework for large-scale identification of hepatitis C virus NS5B inhibitors. J Comput Aided Mol Des 2021;35:1037-53. [PMID: 34622387 DOI: 10.1007/s10822-021-00418-1] [Reference Citation Analysis]
14 Seo DJ, Choi C. Antiviral Bioactive Compounds of Mushrooms and Their Antiviral Mechanisms: A Review. Viruses 2021;13:350. [PMID: 33672228 DOI: 10.3390/v13020350] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 9.0] [Reference Citation Analysis]
15 Mabou Tagne A, Pacchetti B, Sodergren M, Cosentino M, Marino F. Cannabidiol for Viral Diseases: Hype or Hope? Cannabis Cannabinoid Res 2020;5:121-31. [PMID: 32656344 DOI: 10.1089/can.2019.0060] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
16 El-Mowafy M, Elgaml A, El-Mesery M, Sultan S, Ahmed TAE, Gomaa AI, Aly M, Mottawea W. Changes of Gut-Microbiota-Liver Axis in Hepatitis C Virus Infection. Biology (Basel) 2021;10:55. [PMID: 33451143 DOI: 10.3390/biology10010055] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
17 Mazzotta S, Berastegui-Cabrera J, Carullo G, Vega-Holm M, Carretero-Ledesma M, Mendolia L, Aiello F, Iglesias-Guerra F, Pachón J, Vega-Pérez JM, Sánchez-Céspedes J. Serinol-Based Benzoic Acid Esters as New Scaffolds for the Development of Adenovirus Infection Inhibitors: Design, Synthesis, and In Vitro Biological Evaluation. ACS Infect Dis 2021;7:1433-44. [PMID: 33073569 DOI: 10.1021/acsinfecdis.0c00515] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
18 Bobardt M, Hansson MJ, Mayo P, Ure D, Foster R, Gallay P. Structurally distinct cyclosporin and sanglifehrin analogs CRV431 and NV556 suppress established HCV infection in humanized-liver mice. PLoS One 2020;15:e0237236. [PMID: 32764799 DOI: 10.1371/journal.pone.0237236] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
19 Han J, Lee HW, Jin Y, Khadka DB, Yang S, Li X, Kim M, Cho WJ. Molecular design, synthesis, and biological evaluation of bisamide derivatives as cyclophilin A inhibitors for HCV treatment. Eur J Med Chem 2020;188:112031. [PMID: 31923861 DOI: 10.1016/j.ejmech.2019.112031] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
20 Fernandes VS, da Rosa R, Zimmermann LA, Rogério KR, Kümmerle AE, Bernardes LSC, Graebin CS. Antiprotozoal agents: How have they changed over a decade? Arch Pharm (Weinheim) 2021;:e2100338. [PMID: 34661935 DOI: 10.1002/ardp.202100338] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Boehr AK, Arnold JJ, Oh HS, Cameron CE, Boehr DD. 2'-C-methylated nucleotides terminate virus RNA synthesis by preventing active site closure of the viral RNA-dependent RNA polymerase. J Biol Chem 2019;294:16897-907. [PMID: 31575662 DOI: 10.1074/jbc.RA119.010214] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
22 Ramdas V, Talwar R, Banerjee M, Joshi AA, Das AK, Walke DS, Borhade P, Dhayagude U, Loriya R, Gote G, Bommakanti A, Sivaram A, Agarwal G, Goswami A, Nigade P, Mehta M, Patil V, Modi D, Kumar H, Mallurwar S, Dash A, Modi F, Kuldharan S, Srivastava P, Singh M, Narasimham L, Gundu J, Sharma S, Kamboj RK, Palle VP. Discovery and Characterization of Potent Pan-Genotypic HCV NS5A Inhibitors Containing Novel Tricyclic Central Core Leading to Clinical Candidate. J Med Chem 2019;62:10563-82. [PMID: 31710479 DOI: 10.1021/acs.jmedchem.9b01562] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
23 Desideri N, Fioravanti R, Proietti Monaco L, Atzori EM, Carta A, Delogu I, Collu G, Loddo R. Design, Synthesis, Antiviral Evaluation, and SAR Studies of New 1-(Phenylsulfonyl)-1H-Pyrazol-4-yl-Methylaniline Derivatives. Front Chem 2019;7:214. [PMID: 31024899 DOI: 10.3389/fchem.2019.00214] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 2.7] [Reference Citation Analysis]
24 Gao C, Wen C, Li Z, Lin S, Gao S, Ding H, Zou P, Xing Z, Yu Y. Fludarabine Inhibits Infection of Zika Virus, SFTS Phlebovirus, and Enterovirus A71. Viruses 2021;13:774. [PMID: 33925713 DOI: 10.3390/v13050774] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Petković B, Kesić S, Ristić S, Pavković Ž, Podgorac J, Stojadinović G, Pešić V. A New Look at an Old Drug: Cumulative Effects of Low Ribavirin Doses in Amphetamine-Sensitized Rats. Curr Pharm Des 2020;26:3884-94. [PMID: 32213154 DOI: 10.2174/1381612826666200326125821] [Reference Citation Analysis]
26 Leoni S, Casabianca A, Biagioni B, Serio I. Viral hepatitis: Innovations and expectations. World J Gastroenterol 2022; 28(5): 517-531 [DOI: 10.3748/wjg.v28.i5.517] [Reference Citation Analysis]
27 Ma Y, Frutos-Beltrán E, Kang D, Pannecouque C, De Clercq E, Menéndez-Arias L, Liu X, Zhan P. Medicinal chemistry strategies for discovering antivirals effective against drug-resistant viruses. Chem Soc Rev 2021;50:4514-40. [PMID: 33595031 DOI: 10.1039/d0cs01084g] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 11.0] [Reference Citation Analysis]
28 Petković B, Kesić S, Pešić V. Critical View on the Usage of Ribavirin in Already Existing Psychostimulant-Use Disorder. Curr Pharm Des 2020;26:466-84. [PMID: 31939725 DOI: 10.2174/1381612826666200115094642] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
29 Jansen PLM, Breuhahn K, Teufel A, Dooley S. Editorial: Systems Biology and Bioinformatics in Gastroenterology and Hepatology. Front Physiol 2019;10:1438. [PMID: 31824341 DOI: 10.3389/fphys.2019.01438] [Reference Citation Analysis]
30 Luna-Cuadros MA, Chen HW, Hanif H, Ali MJ, Khan MM, Lau DTY. Risk of hepatocellular carcinoma after hepatitis C virus cure. World J Gastroenterol 2022; 28(1): 96-107 [DOI: 10.3748/wjg.v28.i1.96] [Reference Citation Analysis]
31 Majerová T, Novotný P. Precursors of Viral Proteases as Distinct Drug Targets. Viruses 2021;13:1981. [PMID: 34696411 DOI: 10.3390/v13101981] [Reference Citation Analysis]
32 Mahboubi Rabbani SMI, Vahabpour R, Hajimahdi Z, Zarghi A. Design, Synthesis, Molecular Modeling Studies and Biological Evaluation of N'-Arylidene-6-(benzyloxy)-4-oxo-1,4-dihydroquinoline-3-carbohydrazide Derivatives as Novel Anti-HCV Agents. Iran J Pharm Res 2019;18:1790-802. [PMID: 32184846 DOI: 10.22037/ijpr.2019.112186.13586] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
33 Shiner B, Forehand JA, Rozema L, Kulldorff M, Watts BV, Trefethen M, Jiang T, Huybrechts KF, Schnurr PP, Vincenti M, Gui J, Gradus JL. Mining Clinical Data for Novel Posttraumatic Stress Disorder Medications. Biol Psychiatry 2021:S0006-3223(21)01674-7. [PMID: 34952698 DOI: 10.1016/j.biopsych.2021.10.008] [Reference Citation Analysis]
34 Johnson LP, Sterling RK. The Prevalence and Impact of Hepatic Steatosis on Response to Direct-Acting Antiviral Therapy in HIV-HCV Coinfection. Biology (Basel) 2020;9:E87. [PMID: 32344543 DOI: 10.3390/biology9040087] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]